• LifeMD entered an exclusive telehealth co-marketing collaboration with Antares Pharma, a Halozyme subsidiary, for a direct-to-patient self-pay program for XYOSTED.
• Program launch set for July 2026, initially covering 37 states, targeting men diagnosed with hypogonadism through virtual evaluation and lab testing.
• LifeMD’s affiliated medical group will handle clinical assessments; its pharmacy will be the preferred dispenser, shipping XYOSTED to patients’ homes.
• All-in monthly price set at about $249, covering medication, follow-up care, dose management, and refill support, with no insurance required.
• Parties plan joint consumer education and promotional spending; expansion tied to telehealth controlled-substance prescribing rules and potential insurance options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750219) on June 22, 2026, and is solely responsible for the information contained therein.